📊 Key Data
  • 42% reduction in risk of disease progression or death with Imbruvica combination therapy vs. standard chemotherapy.
  • Phase III SHINE trial demonstrated significant improvement in progression-free survival for mantle cell lymphoma patients.
  • Imbruvica is already approved for multiple blood cancers, highlighting its broad oncology potential.
🎯 Expert Consensus

Experts would likely conclude that Imbruvica's combination therapy shows strong efficacy in mantle cell lymphoma, offering a promising new treatment option with regulatory approval potential.

about 8 hours ago
AstraZeneca's Imbruvica Shows Promise in Early-Stage Breast Cancer Trial

AstraZeneca's Imbruvica Shows Promise in Early-Stage Breast Cancer Trial

AstraZeneca's Imbruvica, a targeted cancer therapy, has shown promising results in a late-stage clinical trial for the treatment of patients with a rare form of blood cancer. The Phase III SHINE trial demonstrated a significant improvement in progression-free survival for patients receiving Imbruvica in combination with bendamustine and rituximab compared to standard chemotherapy.

The study involved patients with relapsed or refractory mantle cell lymphoma, a type of non-Hodgkin lymphoma that affects white blood cells. The results showed that the combination therapy reduced the risk of disease progression or death by 42% compared to standard chemotherapy alone.

Dr. Simon Rule, the lead investigator of the study, presented the findings at the American Society of Hematology annual meeting. He noted that the addition of Imbruvica to standard therapy significantly prolonged the time until the disease progressed, offering a potential new treatment option for patients facing this challenging condition.

The positive results from the SHINE trial suggest that Imbruvica could become a valuable addition to the treatment arsenal for mantle cell lymphoma. AstraZeneca plans to submit the data to regulatory authorities for potential approval in this indication.

Imbruvica, jointly developed and commercialized by AbbVie and Janssen Biotech, is already approved for the treatment of several types of blood cancer. Its success in the SHINE trial underscores its potential in addressing unmet medical needs in oncology.

Topics & Related

Sector:
Pharmaceuticals
Oncology
Theme:
Drug Development
Clinical Trials
Event:
Clinical Trial
Product:
Oncology Drugs

📝 This article is still being updated

Are you a relevant expert who could contribute your opinion or insights to this article? We'd love to hear from you. We will give you full credit for your contribution.

Contribute Your Expertise →
UAID: 55290